In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Nephros, with a price target of $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Robert Wasserman’s rating is based on Nephros’s impressive financial performance in the second quarter of 2025, where the company exceeded expectations with a significant increase in revenue and a shift to positive net income. The revenue growth was driven by strong programmatic sales and a substantial order in dialysis filtration, alongside an expansion in active user sites.
Additionally, Nephros has successfully launched new products and expanded its market reach beyond hospitals, contributing to its sales growth. The company also reported improved gross margins and a rise in adjusted EBITDA, strengthening its cash position with no long-term debt. These factors, combined with anticipated revenue growth, support the maintained Speculative Buy rating and a price target that suggests potential price appreciation.
In another report released on August 8, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.